Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : URMD -- Huge market potential -- Ignore unavailable to you. Want to Upgrade?

To: Milk who wrote (249)	4/1/1998 11:26:00 AM
From: Ms. Baby Boomer	Read Replies (1) \| Respond to of 369

Asking 2.25...the magic # 2nd stochastic confirmation > BREAKOUT, reversal in progress [TA this isn't a joke].... Happy April Fools Day!

To: Milk who wrote (249)	5/6/1998 8:51:00 AM
From: Milk	Read Replies (1) \| Respond to of 369

Wednesday May 6, 7:59 am Eastern Time Company Press Release SOURCE: UroMed Corporation U.S. Studies of New Prostate Cancer Surgery Begin Important Technology Available to American Surgeons and Their Patients For the First Time Ever NEEDHAM, Mass., May 6 /PRNewswire/ -- UroMed Corporation (Nasdaq: URMD - news) announced today commencement of its U.S. multicenter clinical study designed to evaluate and quantify the benefits to patients and surgeons utilizing UroMed's unique device -- CaverMap(TM) Surgical Aid -- in order to aid surgeons in sparing vital nerves during prostate cancer surgeries. The CaverMap(TM) Surgical Aid is the first technology cleared for marketing by the U.S. Food and Drug Administration (FDA) to assist surgeons during prostate cancer surgery in locating and helping to spare the cavernosal nerves which are responsible for potency. The most frequent complication of this life-saving surgery is impotence, often caused by intraoperative damage to the cavernosal nerves. Protecting these nerves and preserving potency with the help of the CaverMap(TM) Surgical Aid may offer significant quality of life benefits to the patient. Dr. Patrick C. Walsh, Urologist-in-Chief at the John Hopkins Hospital and a pioneer in the development of nerve sparing techniques stated, ''We are very pleased with our initial experience with this promising technology and we are excited about the potential benefits of using the CaverMap(TM) Surgical Aid. The CaverMap(TM) Surgical Aid may potentially give surgeons the opportunity to improve nerve sparing results, thereby resulting in better post-surgical outcomes for patients.'' Six medical centers are enrolled in the US clinical study and are open for patient inquiries. Participating in the current study are: Patrick C. Walsh M.D., The Johns Hopkins Hospital, Baltimore, M.D.; William J. Catalona M.D., Washington University School of Medicine, St. Louis, MO; Mitchell S. Steiner M.D., University of Tennessee and Urology Center of the South Alliance, Memphis, TN; Robert P. Myers M.D., Mayo Clinic, Rochester, MN; Peter T. Scardino M.D., Baylor College of Medicine, Houston TX and Herbert Lepor M.D., NYU School of Medicine, New York, NY. Each center will conduct operations utilizing this nerve location technology. The centers will record data about the correlation between physicians' expectations and information gathered about the CaverMap(TM) Surgical Aid as well as clinical outcomes relative to potential improvements in the patient's quality of life. The CaverMap(TM) Surgical Aid system is a breakthrough technology that uses state-of-the-art electronics to intra-operatively stimulate and sense the function of the cavernosal nerves responsible for erectile function. This system integrates leading edge nerve stimulation methods, ultra-sensitive technology and ergonomic design tailored for use deep in the pelvic cavity. ''The CaverMap(TM) Surgical Aid is our first offering in the critical area of prostate cancer surgery,'' commented John G. Simon, UroMed's chairman of the board and chief executive officer. '' Initiating the U.S. multicenter study is a milestone for UroMed as it allows us to lay the foundation for the eventual commercial release of this important technology, planned for May of this year. We believe that CaverMap(TM) Surgical Aid nerve sparing offers potentially significant clinical, quality of life and economic benefits.'' It is estimated by industry sources that well over 200,000 new cases of prostate cancer will be diagnosed in the U.S. this year with a large number of these cases expected to be treated by prostate cancer surgery. UroMed, founded in October 1990, is dedicated to establishing itself as a leader in the development of male and female healthcare products. UroMed has developed or acquired technology in three core areas: prostate cancer, urinary incontinence, and breast cancer. UroMed's direct hospital-based business lines include its CaverMap(TM) Surgical Aid, intended to aid physicians in preserving vital nerves during prostate cancer surgery, Iodine125 prostate cancer brachytherapy seeds and its BEACON Technology System(TM), a minimally invasive incontinence surgical line. UroMed's office-based continuum of continence care product lines include the Reliance Insert(R), the INTROL(R) Bladder Neck Support Prosthesis, and the Impress(TM) Softpatch. In breast cancer screening, UroMed is developing its investigational BreastExam(TM), BreastCheck(TM) and Breast View(TM) electronic palpation technology in order to aid physicians and patients in the important mission of finding suspicious breast lumps earlier. UroMed also continues to dedicate significant resources to the development and/or acquisition of product lines that fit into UroMed's strategic platform. INTROL(R) Bladder Neck Support Prosthesis and Reliance(R) Urinary Control Insert are registered trademarks of UroMed Corporation. Impress(TM) Softpatch, PelvicFlex(TM) Personal Trainer Video , BEACON Technology System(TM), BreastCheck(TM) BreastExam(TM) BreastView(TM) and CaverMap(TM) Surgical Aid are trademarks of UroMed Corporation. SOURCE: UroMed Corporation biz.yahoo.com